

Research Paper

## Mutation at Tyrosine in AMLRY (GILRY Like) Motif of Yeast eRF1 on Nonsense Codons Suppression and Binding Affinity to eRF3

Akhmaloka<sup>1</sup>, Prima Endang Susilowati<sup>1,2</sup>, Subandi<sup>3</sup>, Fida Madayanti<sup>1</sup>

1. Biochemistry Research Division, Faculty of Mathematics and Natural Sciences, Institut Teknologi Bandung, Jln Ganesha 10, Bandung, Indonesia.
2. Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universty of Halouleo, Kendari, Indonesia.
3. Department of Chemistry, Faculty of Mathematics and Natural Sciences, State Universty of Malang, Malang, Indonesia.

Correspondence to: Akhmaloka PhD, Biochemistry Research Division, Faculty of Mathematics and Natural Sciences, Institut Teknologi Bandung, Telp 62-22-2515032, fax 62-22-2502360, E-mail: loka@chem.itb.ac.id

Received: 2008.02.17; Accepted: 2008.04.20; Published: 2008.04.21

Termination translation in *Saccharomyces cerevisiae* is controlled by two interacting polypeptide chain release factors, eRF1 and eRF3. Two regions in human eRF1, position at 281-305 and position at 411-415, were proposed to be involved on the interaction to eRF3. In this study we have constructed and characterized yeast eRF1 mutant at position 410 (correspond to 415 human eRF1) from tyrosine to serine residue resulting eRF1(Y410S). The mutations did not affect the viability and temperature sensitivity of the cell. The stop codons suppression of the mutant was analyzed *in vivo* using *PGK-stop codon-LACZ* gene fusion and showed that the suppression of the mutant was significantly increased in all of codon terminations. The suppression on UAG codon was the highest increased among the stop codons by comparing the suppression of the wild type respectively. *In vitro* interaction between eRF1 (mutant and wild type) to eRF3 were carried out using eRF1-(His)<sub>6</sub> and eRF1(Y410S)-(His)<sub>6</sub> expressed in *Escherichia coli* and indigenous *Saccharomyces cerevisiae* eRF3. The results showed that the binding affinity of eRF1(Y410S) to eRF3 was decreased up to 20% of the wild type binding affinity. Computer modeling analysis using Swiss-Prot and Amber version 9.0 programs revealed that the overall structure of eRF1(Y410S) has no significant different with the wild type. However, substitution of tyrosine to serine triggered the structural change on the other motif of C-terminal domain of eRF1. The data suggested that increasing stop codon suppression and decreasing of the binding affinity of eRF1(Y410S) were probably due to the slight modification on the structure of the C-terminal domain.

Key words: eRF1, eRF3, *Saccharomyces cerevisiae*, termination translation, nonsense codon suppression, binding affinity

### INTRODUCTION

Protein biosynthesis is a complex phenomenon involving RNA-RNA, RNA-protein and protein-protein interactions. This process is carried out in three distinct steps: initiation, elongation and termination. While the first two steps have been extensively studied, our understanding of the termination process has lagged behind.

Protein biosynthesis terminates when one of the three stop codons enters the aminoacyl site (A-site) and signals polypeptide chain release from the peptidyl-tRNA located in the ribosomal P-site [1]. The process is facilitated by two general groups of accessory proteins: a class I release factor, codon-specific RFs (RF1 and RF2 in prokaryotes; eRF1 in eukaryotes), and a class II release factor, codon-non specific RFs (RF3 in prokaryotes and eRF3 in eukaryotes) that binds guanine nucleotides-binding proteins possessing GTPase activity [2, 3, 4]. Although the basic biological action of class-1 RFs is similar between prokaryotes and eukaryotes, they exhibit distinct structural and

functional features. Yeast eukaryotic release factor 1 (eRF1) encoded by *SUP45* gene, recognizes any of the three stop codons [5]. Eukaryotic release factor 3 (eRF3) in yeast encoded by *SUP35* gene, stimulates the termination reaction in GTP dependent manner [6, 4]. Following stop codon recognition, eRF1 also induces polypeptide chain release by activating peptidyl transferase center of the ribosome.

Both eRF1 and eRF3 are essential for viability of yeast cells and deletion of the C-terminal part of each protein separately lead to lethality [1]. Crystal structure of human eRF1 has been determined and found that the protein is composed by three domains. The N-terminal domain (domain1) has been proposed to be responsible for stop codon recognition [7]. This proposal was supported by mutational approach [5] and crosslinking experiment [8]. The middle domain (domain 2) is responsible for peptidyl transferase hydrolytic activity and includes a GGQ motif that has been highly conserved through evolution [9]. Mutations in GGQ (Gly residues) are dominant-negative *in vitro*

and lethal in vivo in *S. cerevisiae* cells [7]. The domain 3 corresponds to the C-terminal part of eRF1 that is necessary for the interaction with eRF3 although there are discrepancies in the precise location of the region of eRF1 that interacts with eRF3. Progressive deletion of the C-terminal of eRF1, 6-19 amino acids in *S. cerevisiae* [10] and 17 amino acids of *Schizosaccharomyces pombe* [2] resulted in a corresponding loss of eRF3 binding. In any case, the core eRF3-binding region identified for *Homo sapiens* eRF1 (by the yeast two-hybrid and deletion analysis), showed that two regions in each release factor are critical for mutual binding, position 281-305 and 411-415 (GILRY) of eRF1 and position 478-530 and 628-637 of eRF3 [11]. Although deletion of residues within domain 3 of eRF1 resulted in the loss of eRF3 interaction, however detail position and amino acid residues for the interaction are still unclear yet.

Preliminary study using computer modeling analysis on the structure of yeast eRF1, especially on the above two regions showed that tyrosine at position of 410 (Y410) and threonine at position of 295 (T295) of eRF1 exposed to the surface of molecules. Tyrosine at position of 410 is one of amino acid residues in AMLRY (GILRY like) motif of yeast eRF1 protein. Among of the amino acid residues on the AMLRY motif, tyrosine is one of best possible amino acid residues that contributing on its interaction since this residues containing hydroxyl group. In order to probe the role of tyrosine at AMLRY motif (Y410) of eRF1, here we reported the effect of mutation Y410 on the termination of protein biosynthesis. The nonsense codon suppressions have been used to assay the accuracy of termination process.

## MATERIALS AND METHODS

### Microbial strains, plasmids and growth conditions.

*S. cerevisiae* strains used in this study are listed in Table 1. All strains were *SUQ5* and [*psi*]. Yeast cultures were growth in standard rich medium, YPD (1% (w/v) bacto peptone, 0.5% (w/v) yeast extract, and 2% (w/v) glucose); Y8 (1% (w/v) bacto peptone, 0.5% (w/v) yeast extract, and 8% (w/v) glucose) or minimal medium was used SM (0.67% (w/v) yeast nitrogen base, 2% (w/v) glucose, supplemented with appropriate amino acids) at 30°C with gently shaking. For the plasmid shuffling, the strains were grown on medium YNB-FOA (0.67% (w/v) yeast nitrogen base, 2% (w/v) glucose, 0.1% (w/v) 5-Fluorootic acid (5-FOA), 20 µg/mL uracil).

Plasmid pUKC1901, a shuttle vector between *E. coli* and *S. cerevisiae* cells, carrying *sup45-Y410S* gene was used for construction of other plasmids and  $\Delta$ LE2-Y410S strain. The other plasmid, pUKC815, 817,

818, and 819 were used for nonsense codon readthrough assay on *S. cerevisiae*. All plasmids named by pUKC (Table 2) were gift from M.F. Tuite, University of Kent, United Kingdom.

**Table 1.** Yeast strains used in this study.

Strains	Genotype
Yeast $\Delta$ LE2(803)	<i>SUQ5, ade2-1, his3-11,15, ura3-1, leu2-1, can1-100, [psi-], SUP45::HIS3</i>
Yeast $\Delta$ LE2( <i>SUP45</i> )	<i>SUQ5, ade2-1, his3-11,15, ura3-1, leu2-1, can1-100, [psi-], SUP45::HIS3, [LEU2-1-SUP45 wild-type]</i>
Yeast $\Delta$ LE2(Y410S)	<i>SUQ5, ade2-1, his3-11,15, ura3-1, leu2-1, can1-100, [psi-], SUP45::HIS3, [LEU2-1-sup45-Y410S]</i>

**Table 2.** Plasmid used in this study.

Plasmid	Description
pUKC630	<i>E. coli</i> expression vector carrying <i>SUP45</i> gene with a hexa-histidine sequence under the control of T7 RNA polymerase promoter.
pEPES-Y410S	Similar plasmid with pUKC630 that <i>SUP45</i> was replaced by <i>sup45-Y410S</i>
pUKC1901	<i>S. cerevisiae</i> <i>LEU2</i> based plasmid carrying the <i>sup45-Y410S</i>
pSPES- <i>SUP45</i>	Similar plasmid with pUKC1901 that <i>sup45-Y410S</i> gene was replace by <i>SUP45</i>
pUKC606	Multicopy yeast vector carrying <i>SUP35</i> gene with original promoter
pUKC815	<i>S. cerevisiae</i> <i>URA3</i> based plasmid carrying the <i>PGK-LACZ</i> gene fusion.
pUKC817	<i>S. cerevisiae</i> <i>URA3</i> based plasmid carrying the <i>PGK-TAA-LACZ</i> gene fusion.
pUKC818	<i>S. cerevisiae</i> <i>URA3</i> based plasmid carrying the <i>PGK-TAG-LACZ</i> gene fusion.
pUKC819	<i>S. cerevisiae</i> <i>URA3</i> based plasmid carrying the <i>PGK-TGA-LACZ</i> gene fusion.

### Plasmid Constructions.

Two plasmids, namely pSPES-*SUP45*, and pEPES-Y410S were constructed in this study. To generate plasmids pSPES-*SUP45*, a 1400 bp *Bgl*III-*Hind*III fragments from plasmid pUKC630 containing the entire *SUP45* gene was cloned into *Bgl*III and *Bam*HI sites of plasmid pUKC1901, a shuttle vector of *E. coli* and *S. cerevisiae*. While plasmid pEPES-Y410S was constructed using 1400 bp of *Hind*III-*Bgl*III fragment from plasmid pUKC1901 ligated into *Hind*III and *Bgl*III restriction sites of plasmid pUKC630. All of the plasmids were used to transform *E. coli* DH5 $\alpha$  for propagating the plasmid.

### Plasmid Shuffling.

The plasmid shuffling was carried out based on the standard method [12]. The haploid  $\Delta$ LE2(803) (*SUP45::HIS3, URA3, SUP45*) was used in plasmid shuffling. The strain was transformed with (*LEU2 sup45*) plasmids (pSPES-*SUP45* and pUKC1901). The transformants were selected on medium without uracil and leucine (-Ura -Leu) and then checked by replicating onto 5-FOA medium to counter selects against *URA3* plasmids. Growth was also assayed using serial dilution overnight culture with OD600 = 1. Serially

(10-fold) diluted yeast cell cultures were spotted on plates containing 5-FOA to determine the ability of *sup45* mutant alleles to support cell growth. The wild type of yeast *SUP45* gene carried on *URA3* plasmid eliminates since 5-FOA is toxic to cell expressing the *URA3* gene. The resulting strains,  $\Delta$ LE(*SUP45*) and  $\Delta$ LE(Y410S), were used for further characterization.

### $\beta$ -galactosidase assays.

Centromeric plasmids pUKC815, 817, 818 and 819 [13] were transformed into suppressor strains ( $\Delta$ LE(*SUP45*), and  $\Delta$ LE(Y410S)). The transformants were grown in plasmid-selective medium and  $3 \times 10^6$  cells were inoculated into 5 mL YPD respectively. Triplicate samples from cultures grown to OD<sub>600</sub> ~ 1.0 were treated essentially as described by Coligan *et al.* [14], with the following modifications. The cells were suspended in 500  $\mu$ L Z buffer, 10  $\mu$ L 0.1% SDS and 20  $\mu$ L chloroform. The samples were then vortexed for 15 s and equilibrated for 15 min in a 30°C water bath. After adding 100  $\mu$ L 4 mg/mL O-nitrophenyl- $\beta$ -D-galactosidase (ONPG), samples were vortexed for 5 s and the reaction were carried out for 30 min at 30°C water bath before stopping the reaction by adding 500  $\mu$ L 1M sodium carbonate. After centrifugation at 5000 g, the supernatants were measured at both 420 nm and 550 nm wavelengths and the Miller unit of each samples were calculated as (OD<sub>420</sub>) - (OD<sub>550</sub>  $\times$  1.75). The readthrough for each of the three stop codons was calculated as the percentage of LacZ expression relative to the construct lacking a stop codon (pUKC815) in the same medium.

### Expression of yeast eRF1-(His)6 and eRF1(Y410S)-(His)6 in *E. coli*.

The recombinant plasmid, pUKC630 and pEPES-Y410S containing His-tag gene at the upstream region of *SUP45* or *sup45-Y410S* coding sequences were introduced into *E. coli* BL2(DE3) as host strain for eRF1 expression system. For expression of the gene, the transformants were grown aerobically at 37°C in LB containing ampicillin until the cells density reached  $2 \times 10^8$  cell/mL or OD<sub>600</sub> at around 0.6. The cultures were induced by addition of 0.1 mM IPTG and incubated at 25°C for 4 h with aeration. The cultures were then centrifuged at 5000 g and the pellets were re-suspended in solubilization buffer (50mM Tris-HCl pH 7.4; 200 mM NaCl). Lysis cells were performed by sonication. The samples were centrifuged at 10000 g and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The SDS-PAGE was performed with a 12.5% (w/v) acrylamide gel, and the proteins were stained with commassie blue G-250 [15].

### Preparation of yeast post-mitochondrial supernatants (PMS).

Yeast cultures were grown to a cell density of  $3.5 \times 10^7$  cells/ml. Harvested cells were washed with lysis buffer (25 mM Tris-HCl, pH 7.2, 5 mM MgCl<sub>2</sub>, 5 mM 2-mercaptoethanol and 25 mM KCl) containing 1 mM phenylmethylsulphonyl fluoride (PMSF), 1 mM benzamidine, 10  $\mu$ M leupeptin and 10  $\mu$ M pepstatin A to limit proteolytic degradation. Following washing in lysis buffer, harvested cells were resuspended in a minimum volume of the same buffer. Cells were lysed by vortexing with glass beads and cell debris removed by centrifugation at 13 000 rpm for 15 min in a bench-top microcentrifuge, producing a postmitochondrial supernatant (PMS).

### Immobilization of eRF1-(His)6.

The following operations were performed at room temperature unless otherwise stated and columns were allowed to flow by gravity. A 500  $\mu$ L column of Ni-NTA resin (Qiagen) was equilibrated with 30 mM bis-Tris-HCl, pH 6.8, 0.8 M KCl, 5 mM 2-mercaptoethanol, 30 mM imidazole (buffer A). *E. coli* crude extract containing eRF1-(His)6 and eRF1(Y410S)-(His)6 were passed three times through the resins separately, which were then washed with 10 column vol. buffer A followed by 10 vol. buffer containing 30 mM bis-Tris-HCl, pH 6.2, 1 M KCl, 5 mM 2-mercaptoethanol, 20% glycerol, 30 mM imidazole. This procedure resulted in partial purification and immobilization of eRF1-(His)6 and eRF1(Y410S)-(His)6 on the Ni-NTA resins. In order to assess the binding of eRF3 to the immobilized eRF1-(His)6 and eRF1(Y410S)-(His)6, the resins were equilibrated with 10 column vol. lysis buffer containing 25 mM KCl. A PMS prepared from cells overexpressing eRF3 (transformed with plasmid pUKC606) was then incubated with a suspension of the resin in 25 mM KCl lysis buffer for 2 h on a shaking platform at 4°C. After this time the resin was centrifuged briefly, the supernatant removed and retained and the resins returned to columns for washing with 10 column vol. 25 mM KCl lysis buffer containing 0.15% w/v Tween-20 detergent.

### Computer modelling.

The initial three dimensional structure of eRF1 was constructed by homology protein structure modeling from Swiss-Prot using predict protein program [16]. The comparative modeling program used three steps: alignment of amino acid sequence of yeast eRF1 with the template of human eRF1 [7], PDB number 1DT9.pdb., structure prediction based on primary sequences homology, and validation of the structure using WHAT\_IF program in Swiss-Prot.

Amber version 9.0 program package [17] was


used for the molecular simulation. The structure was subjected to energy minimization calculation by steepest descent method with 500 iterations followed by the conjugate gradient method with 4500 iteration to be used as starting lowest energy structure. Simulation image of the protein was generated using Visual Molecular Dynamic (VMD) software [18]. The Root Mean Square Deviation (RMSD) was calculated for the backbone atoms with reference to starting structure of time 0.

## RESULTS

### Construction characterization of yeast strains, $\Delta$ LE2(*SUP45*) and $\Delta$ LE2(*Y410S*).

$\Delta$ LE2(*SUP45*) and  $\Delta$ LE2(*Y410S*) are haploid yeast strains that carrying chromosomal *SUP45* disrupted by

*HIS3* gene (*SUP45::HIS3*), *SUP45* and *sup45* gene in plasmid pSEPES-*SUP45* and pUKC1901 respectively. The strains were constructed from  $\Delta$ LE2(803), haploid strain which carrying *SUP45::HIS3* and *SUP45* gene in *CEN URA3* based plasmid.  $\Delta$ LE2(803) strain was transformed with *LEU2* based plasmid carrying *SUP45* or *sup45-Y410S* mutant. The transformants were then subjected to plasmid shuffle analysis to verify whether strains containing *sup45-Y410S* could lose the viability (Fig 1A). Transformants carrying *sup45-Y410S* allele and *SUP45* (as control) were able to grow in the presence of 5-FOA, indicating that all tested mutation can replace the wild type of *SUP45* for the viability (data not show). However, plasmid shuffle was less efficient with *sup45* mutants than with the wild type *SUP45*.



**Figure 1.** Shuffling strategy and the phenotype of the transformants. A. Strategy used for plasmid shuffling. (1), *LEU2* based plasmid was introduced to  $\Delta$ LE2(803). (2), double transformant was induced on media containing 5-FOA. B. Phenotypes of transformants.  $\Delta$ LE2(*SUP45*) and  $\Delta$ LE2(*Y410S*) grown on rich medium (Y8), SM medium without leucine (-Leu), SM medium without uracil (-Ura).

The viable transformants on media containing 5-FOA were characterized, including genotypes, temperature sensitivity and the allosuppressor phenotypes to UAA codon in *ade2-1* gene. All of viable cells carrying *SUP45* and *sup45-Y410S* could grow on rich medium (Y8) and synthetic medium without leucine (-Leu), however unable to grow on synthetic medium without uracil (-Ura) (Fig 1B). The viability of the transformants on media -Leu and unviable on media


without uracil showed that *URA3* based plasmid had been replaced by *LEU2* based plasmid. The data confirmed that the plasmid shuffling had been successfully carried out. On rich medium (Y8), the color of transformants carrying wild type *SUP45* gene appeared pink color, while transformants carrying mutation on *sup45-Y410S* showed white color (Fig 1B). This indicating, that *sup45-Y410S* exhibited allosuppressor phenotype. Furthermore, none of the trans-

formants showed temperature sensitive mutants (data not shown).

### Efficiency of $\Delta$ LE2(Y410S) on stop codon suppression.

Stop codon readthrough on  $\Delta$ LE2(Y410S) and  $\Delta$ LE2(SUP45) were measured based on the ability of the cells to terminate the translational process on fusion gene between *PGK-termination codon-LACZ* carried by centromeric (single copy), *URA3* based plasmid [26]. The strains were transformed by each of serial plasmids (pUKC815, 817, 818, and 819). Plasmid pUKC817, 818, and 819 carry UAA, UAG, and UGA termination codons respectively, while plasmid pUKC815 was used as control plasmid without codon termination.

The suppression of  $\Delta$ LE2(Y410S) on all stop codons were significantly increased compared to that the wild type ( $\Delta$ LE2(SUP45)) (Fig 2). The suppression of  $\Delta$ LE2(Y410S) on UAG codon was the highest than that other codons, over 17 times fold than the  $\Delta$ LE2(SUP45). While, the suppression for UGA codon was over 12 times higher than the wild type. Total suppression on UAA codon revealed the highest compared to that the other codons in both mutant and the wild type, this was not surprising since the strains used in this study carrying *SUQ5*, which is a weak tRNA suppressor for UAA codon, genetic background.




**Figure 2.**  $\beta$ -galactosidase assay for  $\Delta$ LE2(SUP45) and  $\Delta$ LE2(Y410S). Vertical axis for % of suppression compared to  $\beta$ -galactosidase activity transformant carrying plasmid pUKC815.

### Binding Affinity of eRF1(Y410S) to eRF3.

eRF1 has been demonstrated to interact with eRF3 *in vitro* [19]. In order to investigate the influence of mutation at Y410S on the interaction to eRF3, the ability of eRF1(Y410S) to precipitate eRF3 was tested

and compared to that the ability of eRF1 wild type. Over expression of eRF1-(His)6 and eRF1(Y410S)-(His)6 were carried out in *E. coli* BL2(DE3) using plasmid pUKC630 and pEPES-Y410S (Fig 3). Four *E. coli* crude extracts, two containing eRF1-(His)6 and other containing eRF1(Y410S)-(His)6, in high salt concentration (0.8 M KCl) lysis buffer, were repeatedly passed through Ni-NTA-agarose resins separately, ensuring preferential binding of the His-tag proteins to the resins and limiting non-specific binding of other proteins. The majority of non-specifically bound proteins were removed by washing the resins under stringent condition of low pH and high salt and glycerol. This resulted in preparation of partially purified eRF1-(His)6 and eRF1(Y410S)-(His)6 bound to nickel resins.



**Figure 3.** SDS-PAGE electrophoregram of crude extract of *E. coli* overexpressed eRF1-(His)6 and eRF1(Y410S)-(His)6.; It is in first without IPTG induction and then with IPTG induction for both couple of lanes 2-3 and 4-5; lanes 1 and 6 are protein molecular markers.

In order to probe the eRF1-eRF3 interaction, the eRF1-(His)6 and eRF1(Y410S)-(His)6 resins were tested for the ability to precipitate eRF3 from solution. eRF3 was overexpressed in yeast strain  $\Delta$ LE2(803) transformed with pUKC606, from which a PMS was prepared. The eRF3-rich PMS was then incubated with either the eRF1-(His)6 resin or eRF1(Y410S)-(His)6 resin for 2 h in a low salt buffer to promote protein-protein interactions. Both eRF1-(His)6 and eRF1(Y410S)-(His)6 resins were then returned to columns to facilitate washing. The control resins were not mixed with eRF3-rich PMS.


Samples of eRF3-rich PMS were analyzed by SDS-PAGE. The results showed that there was no eRF3 detected on the control resins. While for the sample resins, there were some amounts of eRF3 protein. The eRF3 bound to eRF1(Y410S)-(His)6 was less quantity than that on eRF1-(His)6 (Fig 4A). Quantitative analysis of eRF3 bound to the resins were carried out by using densitometric analysis to measure the ratio of eRF3 : eRF1-(His)6 and eRF3 : eRF1(Y410S)-(His)6. The

result showed that the binding affinity of eRF3 to eRF1(Y410S)-(His)<sub>6</sub> was 20% of the eRF3 to the wild type (Fig 4B).

**Structural modeling of eRF1(Y410S).**


Structural modeling of eRF1 mutant and the wild type were performed using Amber 9 program followed by visualization using View Molecular Dynamic (VMD). Based on the Root Mean Square Deviation (RMSD) value, the overall structure of eRF1(Y410S) showed no significant different compared to the wild type (Fig 5A). However detail analysis on the structure of eRF1 third domain showed that eRF1(Y410S) contained secondary structure change (Fig 5 B, C). The

structure of amino acid residues change on eRF1(Y410S) was not in the same motif with the position of mutation (Fig 5C, 1), but in the other motif (Fig 5C, 2). Comparison among the C-terminal domain of human eRF1 (1DT9), yeast eRF1 and eRF1(Y410S) showed that there was 7 amino acid residues from position at 343 - 349 (yeast position) changed from non-helix to helix forms (Fig 6). Ramanchandran Plot between yeast eRF1 and eRF1(Y410S) at the above position (343 - 349) revealed that the residues in eRF1(Y410S) tend to be more stable in helical form (Fig 7).




**Figure 4.** SDS-PAGE electrophoregram of eRF3 bound to eRF1(His)<sub>6</sub> resin and densitometric quantitation. A. Electrophoregram of eRF3 bound to eRF1(His)<sub>6</sub> resin. Lane 1 and 6, purified eRF3 carrying His tag overexpressed in yeast. Lane 2 and 3, eRF1-Y410S(His)<sub>6</sub> resins with (sample) and without (control) eRF3 bound. Lane 4 and 5, eRF1(His)<sub>6</sub> resins without (control) and with (sample) eRF3 bound. B. Comparison between the ratio of eRF3 : eRF1(His)<sub>6</sub> and eRF3 : eRF1-Y410S(His)<sub>6</sub>. The ratio between eRF3 : eRF1(His)<sub>6</sub> used as control (100%).

**Figure 5.** Three dimensional structure of eRF1 and eRF1-Y410S modelling. A. Superposition of eRF1 (red) and eRF1-Y410S (yellow) structures; domain 3 of eRF1 (circle). B and C. Close up structure of eRF1 and eRF1-Y410 domain 3; position of mutation (1), position of structural change before (B) and after (C) mutation (2, and 3).



Yeast eRF1	248	SIVDVSYGGE	NGFNQAIELS	AEALANVKYV	QEKKLEAYF	DEISQDTGKF
eRF1 (Y410S)		SIVDVSYGGE	NGFNQAIELS	AEALANVKYV	QEKKLEAYF	DEISQDTGKF
1dt9A	252	KLVDISYGGE	NGFNQAIELS	TEVLSNVKFI	QEKKLIGRYF	DEISQDTGKY
		.**.* **	*****	* * .**.*	*****	** * ** .**.*
Yeast eRF1		sss	hhhhhhhhh	hhh	hhhhhhhhh	hhh ss
eRF1 (Y410S)		sss	hhhhhhhhh	hhh	hhhhhhhhh	hhh ss
1dt9A		sssss	hhhhhhhhh	hhh	hhhhhhhhh	hhh ss
Yeast eRF1	298	CGIDD-T-KA	LDLGAVEKLI	VFENLETIRY	FKDAEDNEVI	KFAEPEAKDK
eRF1 (Y410S)		CGIDD-T-KA	LDLGAVEKLI	VFENLETIRY	FKDAEDNEVI	KFAEPEAKDK
1dt9A	302	CFGVEDTLKA	LEMGAVEILI	VYENLDIMRY	V-----LI	LYLTPE-QEK
		* . * **	* . **.* **	* . **.*	***	* . ** .*
Yeast eRF1		sss	sss sss	sss	sss	sss
eRF1 (Y410S)		sss	sss sss	sss	sss	h
1dt9A		sss	hhhhhh hh	sss sss	ssss	sss
Yeast eRF1	350	SFAIDKATGQ	EMDVVSEEP	IEWLAANYKN	FGATLEFITD	KSSEGAQFVT
eRF1 (Y410S)		SFAIDKATGQ	EMDVVSEEP	IEWLAANYKN	FGATLEFITD	KSSEGAQFVT
1dt9A	353	----DKSHFT	ESM----PL	LEWFANNYKK	FGATLEIVTD	KSQEGSQFVK
		** .	* .	** . ** . ** . *	***** . ** *	* ** . ** *
Yeast eRF1		hhhhhh	hh hhhh	sssss	hhhhhhhh	hhhhhhhh
eRF1 (Y410S)		hhhhhh	hh hhhh	sssss	hhhhhhhh	hhhhhhhh
1dt9A		hhhhhh	s ssh hhhh	sssss	hhhhhhhh	hhhhhhhh
Yeast eRF1	400	GFGGIGAMLR	YKVNFEQL			
eRF1 (Y410S)		GFGGIGAMLR	SKVNFEQL			
1dt9A	406	GFGGIGGILR	YRVDFQGM-			
		***** . ** *	* . * .			
Yeast eRF1		ssssss				
eRF1 (Y410S)		ssssss				
1dt9A		ssssss				

**Figure 6.** Homological of C-terminal among human, yeast and Y410S of eRF1. 1dt9A, human eRF1; s for beta sheet; h for helix; red bar showed secondary structure change; blue bar showed position of mutation.



**Figure 7.** Ramachandran plot for 11 amino acid residues including 7 amino acid residues changed from non-helix to helix form. A for yeast eRF1; B for eRF1(Y410S).

## DISCUSSION

Domain3 of eRF1 was proposed to be responsible for the interaction with eRF3 protein respectively [2, 20, 21]. Serial deletion on this region have been reported to have defect on its interaction [10], however there was no information concerning the effect of

amino acid substitution in the region. We have constructed and characterized *sup45* mutant which has mutation in codon no 410 for tyrosine to serine. Tyrosine at position 415 in human eRF1 is one of the amino acids that are critical for mutual binding lied on GILRY motif of human eRF1 [11].

*SUP45* is essential gene in haploid *S. cerevisiae* cell [1]. Disruption of the gene causes lethality in haploid yeast cell. In order to assay mutation in the gene *in vivo*, the mutant gene was introduced to  $\Delta$ LE2(803) which carrying disruption of chromosomal *SUP45::HIS3* and *SUP45* gene in single copy *URA3* based plasmid. The transformants containing double plasmid (*URA3* and *LEU2* based plasmids) were subjected for plasmid shuffle [22] by growing the cell on medium containing 5-FOA. The wild type yeast *SUP45* gene carried on the *URA3* plasmid eliminated because 5-FOA is toxic to cell expressing the *URA3* gene [23].

Mutation of *sup45-Y410S* showed an allosuppressor phenotype (Fig 1B).  $\Delta$ LE2(803) carries *ade2* and *SUQ5* in addition of *SUP45::HIS3* and *SUP45 CEN URA3* based plasmid. *SUQ5* is a weak tRNA suppressor [24]. This tRNA suppressor does not suppress nonsense codon on *ade2* mutant on [*psi*-] genetic background [25]. However, mutation on *sup45* gene could enhance the activity of *SUQ5* [26] to suppress nonsense mutation on *ade2* gene. Mutation on *sup45-Y410S* enhanced all of stop codon suppressions (Fig 2). However the quantitative values were variation depend on the type of stop codons. UAA codon was the most readthrough in all strains examined including the wild type. This was not surprising since all strains carrying *SUQ5* genetic background. *SUQ5* is codon specific tRNA suppressor for UAA codon [13]. While on UAG and UGA codons, the suppression of the wild type strain was very low, almost no suppression (Fig 2). However for the mutant strains, the suppression of UAG and UGA were significantly increased. The UAG codon was the mostly leaky codon in the mutant. This was unexpected since eRF1 reported to recognize all of stop codons in the same manner [27, 28, 6].

Termination translation in eukaryotic system that involved interaction between eRF1 and eRF3 is a complex phenomenon. Detail mechanism of the process is still unclear yet. eRF1 was reported to be phosphorylated by CK2 protein but the product did not significantly affect directly to translation termination [29]. Urakov *et al.* [30] demonstrated that IttIp could modulate the efficiency of termination translation in yeast. Meanwhile, recent report showed that eRF1 protein participates not only on termination translation but also in mRNA degradation and translation initiation via interaction with other proteins [22].

In order to characterize the causes of an elevation of suppression in *sup45-Y410S*, *in vitro* interaction of eRF1(Y410S) to eRF3 was examined. The result showed that there was significant reduction on the binding affinity of eRF1(Y410S) to eRF3 (Fig 4). As consequences the suppressor was preferable to recognize the nonsense codons and thus increase the read-through.

Further analysis on three dimensional structures of eRF1(Y410S) showed there was alteration on secondary structure of some amino acids residues from non-helix to helix form (Fig 6). The structural modification in eRF1(Y410S) did not directly affect on the structure of AMLRY motif but triggered structural modification of neighboring motifs (Fig 5C). This modification might affect the interaction of eRF1(Y410S) to eRF3 and thus increasing the suppression of codon terminations.

The AMLRY motif lies at position 406- 410 residues of yeast eRF1 which has 437 amino acid residues. Amino acid substitution in the end of C- or N-terminal of protein usually does not affect the overall structure of the protein since these residues will be stabilized by water solvent. Substitution of tyrosine at position 410 to serine did not significantly affect the overall structure of eRF1 but triggered alteration on the secondary structure of amino acid residues lied at position 343-349. This was quite surprising since the distance of the residues is a far way. Tyrosine and serine both contained hydroxyl group, however, the proton on serine could not ionized while tyrosine does, in addition tyrosine contains bulky functional group and electron dense. These differences in electrostatic and electronic features might affect the probability of secondary structure of surrounding amino acid residues, however simulation result showed that substitution of tyrosine to phenylalanine did not affect the secondary structure of amino acid residues at the above position (unpublished data) so it is unlikely that the bulky functional group and the electron dense caused the structural change. The most possible explanation is that the differences on the properties of hydroxyl group was the key factor for the structural change on the region and thus substitution of tyrosine to serine reduced the energetic state and stabilized secondary structure to form helix (Fig 7).

All the data obtained suggests that tyrosine at AMLRY motif is important amino acid residue for the interaction to eRF3, however the hydroxyl group of tyrosine seems does not directly involve on the binding to eRF3. The intact of three dimensional structure of domain 3 of eRF1 is suggested as a key factor for the interaction to eRF3.

## ACKNOWLEDGMENT

We would like to thank Prof M. F. Tuite, University of Kent, for plasmid and yeast cell gifts. This research was supported by Fundamental Research Grant from Directorate for Higher Education, Department of National Education, Indonesia to AKH, and BPPS scholarship to PES.

## CONFLICT OF INTEREST

The authors have declared that no conflict of interest exists.

## REFERENCES

- Inge-Vechtomov SG, Zhouravleva G, Philippe M. Eukaryotic release factor (eRFs) history (review). *Biology of the Cell*. 2003; 95: 195-209.
- Ito K, Uno M, Nakamura Y. Single amino acid substitution in prokaryotic polypeptide release factor 2 permits it to terminate translation at all three termination codons. *Proc Natl Acad Sci USA* 1998; 95: 8165-8169.
- Kisselev L, Ehrebreg M, Frolova L. Termination of translation: interplay of mRNA, rRNAs and release factor? *Embo J*. 2003; 22: 175-182.
- Salas-Marco J, Bedwell DM. GTP hydrolysis by eRF3 facilitates stop codon decoding during eukaryotic translation termination. *MCB* 2004; 24: 7769-7778.
- Bertram G, Bell HA, Ritchie D, et al. Termination eukaryote translation: domain 1 of release factor eRF1 function in stop codon recognition. *RNA* 2000; 6: 1236-1247.
- Frolova LY, Le GX, Zhouravleva G, et al. Eukaryotic polypeptide chain release factor eRF3 is an eRF1 and ribosom-dependent guanosine triphosphatase. *RNA* 1996; 2: 234-341.
- Song H, Mugnier P, Webb HM, et al. The crystal structure of human eukaryotic release factor eRF1-mechanism of stop codon recognition and peptidyl-tRNA hydrolysis. *Cell* 2000; 100: 311-321.
- Chavatte L, Frolova LY, Kisselev L, et al. The polypeptide chain release factor eRF1 specifically contacts the UGA stop codon located in the A site of eukaryotic ribosomes. *Eur. J. Biochem*. 2001; 268: 2896-2904.
- Frolova LY, Tsivkovskii RY, Sivolobova GF, et al. Mutations in the highly conserved GGQ motif of class 1 polypeptide release factor abolish ability of human eRF1 to trigger peptidyl-tRNA hydrolysis. *RNA* 1999; 5: 1014-1020.
- Eurwilaichitr L, Graves FM, Stansfield I, et al. The C terminus of eRF1 defines a functionally important domain for translation termination in *Saccharomyces cerevisiae*. *Mol. Microbiol*. 1999; 32: 485-496.
- Merkulova TI, Frolova LY, Lazar M, et al. C-terminal domains of human translation termination factors eRF1 and eRF3 mediated their in vivo interaction. *FEBS Letter* 1999; 443: 41-47.
- Kaiser C, Michaelis S, Mitchell A. *Methods in yeast genetics*; Cold Spring Harbor Laboratory Course Manual. New York, USA: Cold Spring Harbor laboratory Press; 1994.
- Stansfield I, Akhmaloka, Tuite M.F. A mutant allele of the *sup45* (*sal4*) gene of *Saccharomyces cerevisiae* shows temperature-dependent allosuppressor and omnipotent suppressor phenotypes. *Curr Genet*. 1995; 27: 417-426.
- Coligan J, Dunn BM, Ploegh HL, et al. *Current Protocols in Protein Science*. New York, USA: Wiley; 1995.
- Sambrook J, Fritsch EF, Maniatis T. *Molecular cloning: a laboratory manual*. Cold Spring Harbor, USA: Cold Spring Harbor Press; 1989.
- Rost B, Yachdav G, Liu J. The Predict Protein server. *Nucleic Acids Research* 2004; 32: W321-W326.
- Case DA, Darden TA, Cheatham TE, et al. *AMBER 9*. San Francisco, USA: University of California; 2006.
- Humphrey W, Dalke A, Schulten K. VMD-visual molecular dynamic. *J. Molec. Graphics* 1996; 14: 33-38.
- Stansfield I, Jones K., Kusnirov VV, et al. The product of the *SUP45* (eRF1) and *SUP35* genes interact to mediate translation termination in *Saccharomyces cerevisiae*. *EMBO J*. 1995; 14: 4365-4373.
- Ebihara K and Nakamura Y. C-terminal interaction of translational release factor eRF1 and eRF3 of fission yeast: G-domain uncoupled binding and the role of conserved amino acid. *RNA* 1999; 5: 739-750.
- Frolova LY, Merkulova TI, Kisselev LL. Translation termination in eukaryotes: polypeptide release factor eRF1 is composed of functionally and structurally distinct domains. *RNA* 2000; 6: 381-390.
- Chabelskaya S, Gryzina V, Moskalenko S, et al. Inactivation of NMD increases viability of *sup45* nonsense mutants in *Saccharomyces cerevisiae*. *BMC Molecular Biology*. 2007; 8:71.
- Boeke JD, LaCrute F, Fink GR. A positive selection for mutants lacking orotidine-5'-phosphate decarboxylase activity in yeast: 5-fluoro-orotic acid resistance. *Mol Genet* 1984; 197: 345-346.
- Cox, B.S. Allosuppressors in yeast. *Ganet Res*. 1977; 30: 187-205.
- Inge-Vechtomov SG, Tikhodeev ON, Karpova TS. Selective system for obtaining recessive ribosomal suppressors in yeast *Saccharomyces cerevisiae*. *Genetika* 1988; 24: 1159-1165.
- Stansfield I, Eurwilaichitr L, Akhmaloka, et al. Depletion in the levels of the release factor eRF1 cause a reduction in the efficiency of translation termination in yeast. *Mol. Microbiol*. 1996; 20: 1135-1143.
- Frolova LY, Le GX, Rasmussen HH, Cheperegin S, et al. A highly conserved eukaryotic protein family possessing properties of polypeptide chain release factor. *Nature* 1994; 372: 701-703.
- Zhouravleva G, Frolova LY, Le GX, et al. Termination of translation in eukaryotes is governed by two interacting polypeptide chain release factor, eRF1 and eRF3. *EMBO J*. 1995; 14: 4065-4373.
- Kallmeyer AK, Keeling KM, Bedwell DM. Eukaryotic release Factor 1 phosphorylation by CK2 protein kinase is dynamic but has little effect on the efficiency of translation termination in *Saccharomyces cerevisiae*. *Eukaryotic Cell* 2006; 5: 1378-1387.
- Urakov VN, Valouev IA, Lewitin EI, et al. Ittlp, a novel protein inhibiting translation termination in *Saccharomyces cerevisiae*. *BMC Molecular Biology* 2001; 2: 9.